NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.75 +0.73 (+0.94%) GOLD FUTURES
2,390.70 +30.80 (+1.31%) DOW
39,828.23 +270.12 (+0.68%) Bitcoin GBP
51,858.62 +3,449.14 (+7.12%)
PolyPid Ltd. (PYPD)
| Previous close | 4.3500 |
| Open | 4.5750 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.5750 - 4.5750 |
| 52-week range | 3.5660 - 13.2000 |
| Volume | |
| Avg. volume | 3,185 |
| Market cap | 23.913M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Approximately 50 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Com
- GlobeNewswire
PolyPid to Participate in Citizens JMP Life Sciences Conference
PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024. Citizens JMP Life Sciences Conference PresentationDate: Monday, May 13, 2024Time:2:30 PM ET The PolyPid management team will participate in one-on-one investor meeting
- GlobeNewswire
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Second Half of 2024 PETACH TIKVA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the 200th patient in its ongoing SHIELD II Phase
